Loading…

Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study

Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present...

Full description

Saved in:
Bibliographic Details
Published in:Aviation, space, and environmental medicine space, and environmental medicine, 2014-06, Vol.85 (6), p.638-644
Main Authors: Weerts, Aurélie P, Vanspauwen, Robby, Fransen, Erik, Jorens, Philippe G, Van de Heyning, Paul H, Wuyts, Floris L
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83
cites
container_end_page 644
container_issue 6
container_start_page 638
container_title Aviation, space, and environmental medicine
container_volume 85
creator Weerts, Aurélie P
Vanspauwen, Robby
Fransen, Erik
Jorens, Philippe G
Van de Heyning, Paul H
Wuyts, Floris L
description Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present study was to identify the effects of meclizine (25 mg), dimenhydrinate (40 mg) combined with cinnarizine (25 mg), and promethazine (25 mg) combined with d-amphetamine (10 mg) on the SCCs and the otoliths. This double-blind, placebo-controlled study was performed on 20 healthy men. Function of the SCC was evaluated by means of an electronystagmography, whereas utricular function was assessed by a unilateral centrifugation test. A cervical vestibular evoked myogenic potentials test evaluated saccular function. Meclizine (0.54 +/- 0.05 vs. 0.38 +/- 0.06) and dimenhydrinate with cinnarizine (0.54 +/- 0.05 vs. 0.45 +/- 0.05) decreased the vestibulo-ocular reflex gain. Promethazine with d-amphetamine decreased the latency of the saccadic eye response (right eye: 185 +/- 3.8 ms vs. 165 +/- 4.5 ms; left eye: 181 +/- 4.9 ms vs. 165 +/- 4.8 ms) and also increased the phase of ocular counterrolling measured during unilateral centrifugation (0.32 +/- 0.35 degrees vs. 1.5 +/- 0.45 degrees). It is hypothesized that meclizine and dimenhydrinate with cinnarizine affect the medial vestibular nucleus. Promethazine is a vestibular suppressor, but study results show that d-amphetamine counterbalances this depression and abolishes the effect of fatigue on the saccadic reaction time The hypothesis that a SCC-suppression alleviates SMS should be further evaluated.
doi_str_mv 10.3357/asem.3865.2014
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1677981727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1560116510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83</originalsourceid><addsrcrecordid>eNqNkTtPwzAURj2AaCmsjMgjAyl-xI-wVVV5SEUMhdmyHQcCThzsZOi_J1ULK0x3OfcM3wHgAqM5pUzc6OSaOZWczQnC-RGYIlSwjDNOJuA0pQ-EEM0JOgETkhe4oJJNgdp02jrYhL4OLUy1_WxdStCGoe1dbJxOQ3TpFmrYvevYaBt8eKut9rAMg_EuM75uy2vY-VFjQmZD28fgvSth6odyewaOK-2TOz_cGXi9W70sH7L18_3jcrHObC5In-WCcpqXFBuBkdCVE0bnwmKEiS5kTgmyhJaiEiUVxlSVZJVhgiKnBSdSSzoDV3tvF8PX4FKvmjpZ571uXRiSwlyIQmJBxN8o4whjzjD6B0rHdTmXZETne9TGkFJ0lepi3ei4VRipXR612Kye1C6P2uUZHy4P7sE0rvzFf9rQb_5tjU0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1535626682</pqid></control><display><type>article</type><title>Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study</title><source>IngentaConnect Journals</source><creator>Weerts, Aurélie P ; Vanspauwen, Robby ; Fransen, Erik ; Jorens, Philippe G ; Van de Heyning, Paul H ; Wuyts, Floris L</creator><creatorcontrib>Weerts, Aurélie P ; Vanspauwen, Robby ; Fransen, Erik ; Jorens, Philippe G ; Van de Heyning, Paul H ; Wuyts, Floris L</creatorcontrib><description>Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present study was to identify the effects of meclizine (25 mg), dimenhydrinate (40 mg) combined with cinnarizine (25 mg), and promethazine (25 mg) combined with d-amphetamine (10 mg) on the SCCs and the otoliths. This double-blind, placebo-controlled study was performed on 20 healthy men. Function of the SCC was evaluated by means of an electronystagmography, whereas utricular function was assessed by a unilateral centrifugation test. A cervical vestibular evoked myogenic potentials test evaluated saccular function. Meclizine (0.54 +/- 0.05 vs. 0.38 +/- 0.06) and dimenhydrinate with cinnarizine (0.54 +/- 0.05 vs. 0.45 +/- 0.05) decreased the vestibulo-ocular reflex gain. Promethazine with d-amphetamine decreased the latency of the saccadic eye response (right eye: 185 +/- 3.8 ms vs. 165 +/- 4.5 ms; left eye: 181 +/- 4.9 ms vs. 165 +/- 4.8 ms) and also increased the phase of ocular counterrolling measured during unilateral centrifugation (0.32 +/- 0.35 degrees vs. 1.5 +/- 0.45 degrees). It is hypothesized that meclizine and dimenhydrinate with cinnarizine affect the medial vestibular nucleus. Promethazine is a vestibular suppressor, but study results show that d-amphetamine counterbalances this depression and abolishes the effect of fatigue on the saccadic reaction time The hypothesis that a SCC-suppression alleviates SMS should be further evaluated.</description><identifier>ISSN: 0095-6562</identifier><identifier>DOI: 10.3357/asem.3865.2014</identifier><identifier>PMID: 24919385</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Antiemetics - therapeutic use ; Depression ; Dimenhydrinate ; Double-Blind Method ; Fatigue (materials) ; Healthy Volunteers ; Histamine H1 Antagonists - therapeutic use ; Humans ; Male ; Meclizine ; Middle Aged ; Motion sickness ; Nuclei ; Promethazine ; Semicircular canals ; Space life sciences ; Space Motion Sickness - drug therapy ; Young Adult</subject><ispartof>Aviation, space, and environmental medicine, 2014-06, Vol.85 (6), p.638-644</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24919385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weerts, Aurélie P</creatorcontrib><creatorcontrib>Vanspauwen, Robby</creatorcontrib><creatorcontrib>Fransen, Erik</creatorcontrib><creatorcontrib>Jorens, Philippe G</creatorcontrib><creatorcontrib>Van de Heyning, Paul H</creatorcontrib><creatorcontrib>Wuyts, Floris L</creatorcontrib><title>Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study</title><title>Aviation, space, and environmental medicine</title><addtitle>Aviat Space Environ Med</addtitle><description>Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present study was to identify the effects of meclizine (25 mg), dimenhydrinate (40 mg) combined with cinnarizine (25 mg), and promethazine (25 mg) combined with d-amphetamine (10 mg) on the SCCs and the otoliths. This double-blind, placebo-controlled study was performed on 20 healthy men. Function of the SCC was evaluated by means of an electronystagmography, whereas utricular function was assessed by a unilateral centrifugation test. A cervical vestibular evoked myogenic potentials test evaluated saccular function. Meclizine (0.54 +/- 0.05 vs. 0.38 +/- 0.06) and dimenhydrinate with cinnarizine (0.54 +/- 0.05 vs. 0.45 +/- 0.05) decreased the vestibulo-ocular reflex gain. Promethazine with d-amphetamine decreased the latency of the saccadic eye response (right eye: 185 +/- 3.8 ms vs. 165 +/- 4.5 ms; left eye: 181 +/- 4.9 ms vs. 165 +/- 4.8 ms) and also increased the phase of ocular counterrolling measured during unilateral centrifugation (0.32 +/- 0.35 degrees vs. 1.5 +/- 0.45 degrees). It is hypothesized that meclizine and dimenhydrinate with cinnarizine affect the medial vestibular nucleus. Promethazine is a vestibular suppressor, but study results show that d-amphetamine counterbalances this depression and abolishes the effect of fatigue on the saccadic reaction time The hypothesis that a SCC-suppression alleviates SMS should be further evaluated.</description><subject>Adult</subject><subject>Antiemetics - therapeutic use</subject><subject>Depression</subject><subject>Dimenhydrinate</subject><subject>Double-Blind Method</subject><subject>Fatigue (materials)</subject><subject>Healthy Volunteers</subject><subject>Histamine H1 Antagonists - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Meclizine</subject><subject>Middle Aged</subject><subject>Motion sickness</subject><subject>Nuclei</subject><subject>Promethazine</subject><subject>Semicircular canals</subject><subject>Space life sciences</subject><subject>Space Motion Sickness - drug therapy</subject><subject>Young Adult</subject><issn>0095-6562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqNkTtPwzAURj2AaCmsjMgjAyl-xI-wVVV5SEUMhdmyHQcCThzsZOi_J1ULK0x3OfcM3wHgAqM5pUzc6OSaOZWczQnC-RGYIlSwjDNOJuA0pQ-EEM0JOgETkhe4oJJNgdp02jrYhL4OLUy1_WxdStCGoe1dbJxOQ3TpFmrYvevYaBt8eKut9rAMg_EuM75uy2vY-VFjQmZD28fgvSth6odyewaOK-2TOz_cGXi9W70sH7L18_3jcrHObC5In-WCcpqXFBuBkdCVE0bnwmKEiS5kTgmyhJaiEiUVxlSVZJVhgiKnBSdSSzoDV3tvF8PX4FKvmjpZ571uXRiSwlyIQmJBxN8o4whjzjD6B0rHdTmXZETne9TGkFJ0lepi3ei4VRipXR612Kye1C6P2uUZHy4P7sE0rvzFf9rQb_5tjU0</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Weerts, Aurélie P</creator><creator>Vanspauwen, Robby</creator><creator>Fransen, Erik</creator><creator>Jorens, Philippe G</creator><creator>Van de Heyning, Paul H</creator><creator>Wuyts, Floris L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>8FD</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>L7M</scope></search><sort><creationdate>20140601</creationdate><title>Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study</title><author>Weerts, Aurélie P ; Vanspauwen, Robby ; Fransen, Erik ; Jorens, Philippe G ; Van de Heyning, Paul H ; Wuyts, Floris L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Antiemetics - therapeutic use</topic><topic>Depression</topic><topic>Dimenhydrinate</topic><topic>Double-Blind Method</topic><topic>Fatigue (materials)</topic><topic>Healthy Volunteers</topic><topic>Histamine H1 Antagonists - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Meclizine</topic><topic>Middle Aged</topic><topic>Motion sickness</topic><topic>Nuclei</topic><topic>Promethazine</topic><topic>Semicircular canals</topic><topic>Space life sciences</topic><topic>Space Motion Sickness - drug therapy</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Weerts, Aurélie P</creatorcontrib><creatorcontrib>Vanspauwen, Robby</creatorcontrib><creatorcontrib>Fransen, Erik</creatorcontrib><creatorcontrib>Jorens, Philippe G</creatorcontrib><creatorcontrib>Van de Heyning, Paul H</creatorcontrib><creatorcontrib>Wuyts, Floris L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Technology Research Database</collection><collection>ANTE: Abstracts in New Technology &amp; Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Advanced Technologies Database with Aerospace</collection><jtitle>Aviation, space, and environmental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weerts, Aurélie P</au><au>Vanspauwen, Robby</au><au>Fransen, Erik</au><au>Jorens, Philippe G</au><au>Van de Heyning, Paul H</au><au>Wuyts, Floris L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study</atitle><jtitle>Aviation, space, and environmental medicine</jtitle><addtitle>Aviat Space Environ Med</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>85</volume><issue>6</issue><spage>638</spage><epage>644</epage><pages>638-644</pages><issn>0095-6562</issn><abstract>Space motion sickness (SMS), caused by a canal-otolith conflict, is currently treated with intramuscular promethazine. However, the drug has an inconsistent efficacy against SMS. We hypothesize that pharmacological depression of the semicircular canals (SCC) might relieve SMS. The aim of the present study was to identify the effects of meclizine (25 mg), dimenhydrinate (40 mg) combined with cinnarizine (25 mg), and promethazine (25 mg) combined with d-amphetamine (10 mg) on the SCCs and the otoliths. This double-blind, placebo-controlled study was performed on 20 healthy men. Function of the SCC was evaluated by means of an electronystagmography, whereas utricular function was assessed by a unilateral centrifugation test. A cervical vestibular evoked myogenic potentials test evaluated saccular function. Meclizine (0.54 +/- 0.05 vs. 0.38 +/- 0.06) and dimenhydrinate with cinnarizine (0.54 +/- 0.05 vs. 0.45 +/- 0.05) decreased the vestibulo-ocular reflex gain. Promethazine with d-amphetamine decreased the latency of the saccadic eye response (right eye: 185 +/- 3.8 ms vs. 165 +/- 4.5 ms; left eye: 181 +/- 4.9 ms vs. 165 +/- 4.8 ms) and also increased the phase of ocular counterrolling measured during unilateral centrifugation (0.32 +/- 0.35 degrees vs. 1.5 +/- 0.45 degrees). It is hypothesized that meclizine and dimenhydrinate with cinnarizine affect the medial vestibular nucleus. Promethazine is a vestibular suppressor, but study results show that d-amphetamine counterbalances this depression and abolishes the effect of fatigue on the saccadic reaction time The hypothesis that a SCC-suppression alleviates SMS should be further evaluated.</abstract><cop>United States</cop><pmid>24919385</pmid><doi>10.3357/asem.3865.2014</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0095-6562
ispartof Aviation, space, and environmental medicine, 2014-06, Vol.85 (6), p.638-644
issn 0095-6562
language eng
recordid cdi_proquest_miscellaneous_1677981727
source IngentaConnect Journals
subjects Adult
Antiemetics - therapeutic use
Depression
Dimenhydrinate
Double-Blind Method
Fatigue (materials)
Healthy Volunteers
Histamine H1 Antagonists - therapeutic use
Humans
Male
Meclizine
Middle Aged
Motion sickness
Nuclei
Promethazine
Semicircular canals
Space life sciences
Space Motion Sickness - drug therapy
Young Adult
title Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A35%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Space%20motion%20sickness%20countermeasures:%20a%20pharmacological%20double-blind,%20placebo-controlled%20study&rft.jtitle=Aviation,%20space,%20and%20environmental%20medicine&rft.au=Weerts,%20Aur%C3%A9lie%20P&rft.date=2014-06-01&rft.volume=85&rft.issue=6&rft.spage=638&rft.epage=644&rft.pages=638-644&rft.issn=0095-6562&rft_id=info:doi/10.3357/asem.3865.2014&rft_dat=%3Cproquest_cross%3E1560116510%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c472t-473634d31b7107afe7ba47c1012a984320c23d7f7d37bbff85fb5730ea7628a83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1535626682&rft_id=info:pmid/24919385&rfr_iscdi=true